First American Financial Corporation Declares Quarterly Cash Dividend of 55 Cents Per Share

SANTA ANA, Calif.--(BUSINESS WIRE)-- First American Financial Corporation (NYSE: FAF), a premier provider of title, settlement and risk solutions for real estate transactions and the leader in the digital transformation of its industry, today announced that its board of directors has declared a quarterly cash dividend of 55 cents per common share.

The cash dividend is payable on June 15, 2026 to shareholders of record as of June 8, 2026.

About First American

First American Financial Corporation (NYSE: FAF) is a premier provider of title, settlement, and risk solutions for real estate transactions. With its combination of financial strength and stability built over more than 135 years, innovative proprietary technologies, and unmatched data assets, the company is leading the digital transformation of its industry. First American also provides data products to the title industry and other third parties; valuation products and services; mortgage subservicing; home warranty products; banking, trust and wealth management services; and other related products and services. With total revenue of $7.5 billion in 2025, the company offers its products and services directly and through its agents throughout the United States and abroad. In 2026, First American was named one of the 100 Best Companies to Work For by Great Place to Work® and Fortune Magazine for the eleventh consecutive year. More information about the company can be found at www.firstam.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260512836980/en/

Media Contact:
Marcus Ginnaty
Corporate Communications
First American Financial Corporation
714-250-3298

Investor Contact:
Craig Barberio
Investor Relations
First American Financial Corporation
714-250-5214

Source: First American Financial Corporation

You May Also Be Interested In

• Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
• Why Smart Teams Are Reassessing Marketing Resource Management Software
• Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P